APPROPRIATE USE OF SGLT2S AND GLP-1RAS WITH INSULIN TO REDUCE CVD RISK IN PATIENTS WITH DIABETES

Course overview

PATIENTS WITH TYPE 2 DIABETES MELLITUS ARE PRONE TO VARIOUS CARDIOVASCULAR RISKS, INCLUDING HYPERTENSION AND DYSLIPIDEMIA, AND THE RISK OF DEVELOPING CORONARY VASCULAR DISEASE LEADING TO MYOCARDIAL INFARCTION AND STROKE. CO-MORBIDITIES SUCH AS HYPERTENSION AND DYSLIPIDEMIA MUST BE WELL CONTROLLED TO MINIMIZE CARDIOVASCULAR RISKS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. ADDITIONALLY, CLINICIANS SHOULD RECOMMEND THAT PATIENTS OBTAIN BETTER GLYCEMIC CONTROL, AS WELL AS MAKE APPROPRIATE LIFESTYLE CHANGES SUCH AS TOBACCO CESSATION, INCREASING EXERCISE, AND REDUCING BODY WEIGHT. THIS ACTIVITY DESCRIBES THE EVALUATION AND MANAGEMENT OF CARDIOVASCULAR RISKS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS USING SGLT2S AND GLP-1RAS DRUGS IN CONJUNCTION WITH INSULIN AND HIGHLIGHTS THE ROLE OF THE INTERPROFESSIONAL TEAM IN IMPROVING CARE FOR PATIENTS WITH THESE CONDITIONS.